Rheumatoid Arthritis: Current and Emerging Paradigms of Diagnosis and Treatment
Pharmaceutical sciences- Pharmaceutics
DOI:
https://doi.org/10.22376/ijlpr.2023.13.6.P170-P191Keywords:
Rheumatoid arthritis (RA), Environmental factors, Genetic factors, DCE-MRI, NSAIDS, and Nanotechnology.Abstract
Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by inflammation and damage to joints andtissues. While previous reviews exist, there still needs to be more in understanding risk factors, diagnostic methods, and treatmentoptions. This review aims to fill these gaps by providing a comprehensive overview of recent advancements in the field. To addressthe limitations of previous reviews, this article incorporates updated information on risk factors, including the influence ofenvironmental factors in industrialized nations. It highlights the significance of early RA diagnosis and emphasizes the utility ofdynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) for effective disease management. Moreover, this reviewintroduces innovative nanotechnology-based treatment approaches for RA. It explores the potential of gold nanoparticles, carbonnanotubes, polymer-based nanomedicine, and nanoliposomes in targeting specific inflammatory sites and improving treatmenteffectiveness. This review aims to present an up-to-date and comprehensive analysis of RA, bridging gaps in previous literature byintroducing novel diagnostic techniques and exploring emerging treatment modalities. By synthesizing current knowledge andoutlining future research prospects, this review aims to advance the understanding and treatment of rheumatoid arthritis.Additionally, this review discusses the systemic complications associated with RA, such as rheumatoid vasculitis and Feltysyndrome. It also sheds light on the long-term consequences of untreated RA, including the potential need for joint replacementsurgery (arthroplasty) and splenectomy. By providing a comprehensive analysis of these aspects, this review aims to enhance theholistic understanding of RA and guide future research toward improved management and patient outcomes.
References
Petrelli F, Mariani FM, Alunno A, Puxeddu I. Pathogenesis of rheumatoid arthritis: one year in review 2022. Clin Exp Rheumatol. 2022;40(3):475-82. doi: 10.55563/clinexprheumatol/l9lyen. PMID 35333708.
Chen X, Wang K, Lu T, Wang J, Zhou T, Tian J, et al. Qiao adiponectin is negatively associated with disease activity and Sharp score in treatment-native Han Chinese rheumatoid arthritis patients. Sci Rep. 2022;12(1):1. doi: 10.1038/s41598-022-10069-9.
Finckh A, Gilbert B, Hodkinson D, Lauper K. Global epidemiology of rheumatoid arthritis. Nat Rev Rheumatol. 2022;18(10):591-602. doi: 10.1038/s41584-022-00756-5.
Liang HY, Yin HX, Li SF, Chen Y, Zhao YJ, Hu W, et al. Calcium-Permeable Channels Cooperation for rheumatoid arthritis: therapeutic opportunities. Biomolecules. 2022;12(10):1383. doi: 10.3390/biom12101383, PMID 36291594.
Dijkshoorn B, Raadsen R, Nurmohamed MT. Cardiovascular disease risk in rheumatoid arthritis anno 2022. J Clin Med. 2022;11(10):2704. doi: 10.3390/jcm11102704, PMID 35628831.
Hadwen B, Stranges S, Barra L. Risk factors for hypertension in rheumatoid arthritis patients—A systematic review. Autoimmun Rev. 2021;20(4):102786. doi: 10.1016/j.autrev.2021.102786, PMID 33609791.
Pan W, Li Z, Qiu S, Dai C, Wu S, Zheng X, et al. Octahedral Pt-MOF with Au deposition for plasmonic effect and Schottky junction enhanced hydrogen thermal therapy of rheumatoid arthritis. Mater Today Bio. 2022;13:100214. doi: 10.1016/j.mtbio.2022.100214, PMID 35198962.
Karstensen JK, Primdahl J, Andersson MLE, Christensen JR, Bremander A. Lifestyle factors in patients with rheumatoid arthritis—a cross-sectional study on two Scandinavian cohorts. Clin Rheumatol. 2022;41(2):387-98. doi: 10.1007/s10067-021-05905-2, PMID 34505213.
Kmiołek T, Paradowska-Gorycka A. miRNAs as biomarkers and possible therapeutic strategies in rheumatoid arthritis. Cells. 2022;11(3):452. doi: 10.3390/cells11030452, PMID 35159262.
Yerima A, Akintayo R, Adebajo A. Implications of a diagnosis of rheumatoid arthritis in resource-poor countries. Best Pract Res Clin Rheumatol. 2022;36(1):101725. doi: 10.1016/j.berh.2021.101725, PMID 34906416.
Elsayed MMA, Aboelez MO, Elsadek BEM, Sarhan HA, Khaled KA, Belal A, et al. Tolmetin sodium fast dissolving tablets for rheumatoid arthritis treatment: preparation and optimization using Box-Behnken design and response surface methodology. Pharmaceutics. 2022 Apr;14(4):880. doi: 10.3390/pharmaceutics14040880, PMID 35456714.
Gerlag DM, Raza K, van Baarsen LG, Brouwer E, Buckley CD, Burmester GR, et al. EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. Ann Rheum Dis. 2012;71(5):638-41. doi: 10.1136/annrheumdis-2011-200990, PMID 22387728.
Zaccardelli A, Friedlander HM, Ford JA, Sparks JA. Potential of lifestyle changes for reducing the risk of developing rheumatoid arthritis: is an ounce of prevention worth a pound of cure? Clin Ther. 2019;41(7):1323-45. doi: 10.1016/j.clinthera.2019.04.021, PMID 31196646.
Liu X, Tedeschi SK, Barbhaiya M, Leatherwood CL, Speyer CB, Lu B, et al. Impact and timing of Smoking Cessation on reducing risk of rheumatoid arthritis among women in the nurses’ health studies. Arthritis Care Res (Hoboken). 2019;71(7):914-24. doi: 10.1002/acr.23837, PMID 30790475.
Gan RW, Demoruelle MK, Deane KD, Weisman MH, Buckner JH, Gregersen PK, et al. Omega-3 fatty acids are associated with a lower prevalence of autoantibodies in shared epitope-positive subjects at risk for rheumatoid arthritis. Ann Rheum Dis. 2017;76(1):147-52. doi: 10.1136/annrheumdis-2016-209154, PMID 27190099.
Mankia K, Cheng Z, Do T, Hunt L, Meade J, Kang J, et al. Prevalence of periodontal disease and periodontopathic bacteria in anti-cyclic citrullinated protein antibody-positive at-risk adults without arthritis. JAMA Netw Open. 2019;2(6):e195394. doi: 10.1001/jamanetworkopen.2019.5394, PMID 31173126.
Polinski KJ, Bemis EA, Feser M, Seifert J, Demoruelle MK, Striebich CC, et al. Perceived stress and inflammatory arthritis: a prospective investigation in the Studies of the Etiologies of Rheumatoid Arthritis (SERA) cohort. Arthritis Care Res (Hoboken). 2019.
Ramos-Remus C, Castillo-Ortiz JD, Aguilar-Lozano L, Padilla-Ibarra J, Sandoval-Castro C, Vargas-Serafin CO, et al. Autoantibodies in prediction of the development of rheumatoid arthritis among healthy relatives of patients with the disease. Arthritis Rheumatol. 2015;67(11):2837-44. doi: 10.1002/art.39297, PMID 26245885 [ this ref is also in current prediction model].
Kolfenbach JR, Deane KD, Derber LA, O’Donnell C, Weisman MH, Buckner JH, et al. A prospective approach to investigating the natural history of preclinical rheumatoid arthritis (RA) using first-degree relatives of probands with RA. Arthritis Rheum. 2009;61(12):1735-42. doi: 10.1002/art.24833, PMID 19950324.
Tanner S, Dufault B, Smolik I, Meng X, Anaparti V, Hitchon C, et al. A prospective study of the development of inflammatory arthritis in the family members of indigenous North American people with rheumatoid arthritis. Arthritis Rheumatol. 2019;71(9):1494-503. doi: 10.1002/art.40880, PMID 30861615.
Kim SK, Bae J, Lee H, Kim JH, Park SH, Choe JY. Greater prevalence of seropositivity for anti-cyclic citrullinated peptide antibody in unaffected first-degree relatives in multicase rheumatoid arthritis-affected families. Korean J Intern Med. 2013;28(1):45-53. doi: 10.3904/kjim.2013.28.1.45, PMID 23345996.
Gonzalez-Lopez L, Gamez-Nava JI, Jhangri G, Russell AS, Suarez-Almazor ME. Decreased progression to rheumatoid arthritis or other connective tissue diseases in patients with palindromic rheumatism treated with antimalarials. J Rheumatol. 2000;27(1):41-6. PMID 10648016.
Burgers LE, Raza K, van der Helm-van Mil AH. Window of opportunity in rheumatoid arthritis - definitions and supporting evidence: from old to new perspectives. RMD Open. 2019;5(1):e000870. doi: 10.1136/rmdopen-2018-000870, PMID 31168406.
Bos WH, Dijkmans BA, Boers M, van de Stadt RJ, van Schaardenburg D. Effect of dexamethasone on autoantibody levels and arthritis development in patients with arthralgia: a randomised trial. Ann Rheum Dis. 2010;69(3):571-4. doi: 10.1136/ard.2008.105767, PMID 19363022.
Gerlag DM, Safy M, Maijer KI, Tang MW, Tas SW, Starmans-Kool MJF, et al. Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study. Ann Rheum Dis. 2018.
Strategy to prevent the onset of clinically apparent rheumatoid arthritis (StopRA). NCT02603146. ClinicalTrials.gov [cited May 1 2020]. Available from: https://clinicaltrials.gov/ct2/show/NCT02603146.
Al-Laith M, Jasenecova M, Abraham S, Bosworth A, Bruce IN, Buckley CD, et al. Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol. Trials. 2019;20(1):429. doi: 10.1186/s13063-019-3403-7, PMID 31307535.
Statins to prevent rheumatoid arthritis (STAPRA) (Netherlands trial register trial NL5036) [cited May 1 2020]. Available from: https://www.trialregister.nl/trial/5036.
Treat early arthralgia to reverse or limit impending exacerbation to rheumatoid arthritis (TREAT EARLIER) (Netherlands Trial Register NL4599) [cited May 1 2020]. Available from: https://www.trialregister.nl/trial/4599.
McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011 Dec 8;365(23):2205-19. doi: 10.1056/NEJMra1004965, PMID 22150039.
Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010 Sep 25;376(9746):1094-108. doi: 10.1016/S0140-6736(10)60826-4, PMID 20870100.
Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016 Oct 22;388(10055):2023-38. doi: 10.1016/S0140-6736(16)30173-8, PMID 27156434.
Karonitsch T, Smolen JS. The role of natural killer cells in rheumatoid arthritis: a review. Autoimmun Rev. 2020;19(4):102511. doi: 10.1016/j.autrev.2020.102511.
Zhang X, Zhang D, Jia H, Feng Q, Wang D, Liang D et al. The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment. Nat Med. 2015;21(8):895-905. doi: 10.1038/nm.3914, PMID 26214836.
Okada Y, Wu D, Trynka G, Raj T, Terao C, Ikari K et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature. 2014;506(7488):376-81. doi: 10.1038/nature12873, PMID 24390342.
Florescu A, Gherghina FL, Mușetescu AE, Pădureanu V, Roșu A, Florescu MM, et al. Novel biomarkers, diagnostic and therapeutic approach in rheumatoid arthritis interstitial lung disease—A narrative review. Biomedicines. 2022;10(6):1367. doi: 10.3390/biomedicines10061367, PMID 35740390.
Dewing KA, Setter SM, Slusher BA. Osteoarthritis and rheumatoid arthritis 2012: pathophysiology, diagnosis, and treatment 2012. In: Nurse practitioner healthcare foundation, ed. Rheumatology: An Annual Review. Philadelphia: Nurse Practitioner Healthcare Foundation; 2012. p. 1-20.
Vetchinkina EA, Mikhaylenko DS, Kuznetsova EB, Deryagina TA, Alekseeva EA, Bure IV, et al. Genetic factors of predisposition and clinical characteristics of rheumatoid arthritis in Russian patients. J Pers Med. 2021 Jun;11(6):469. doi: 10.3390/jpm11060469, PMID 34070522.
Larid G, Pancarte M, Offer G, Clavel C, Martin M, Pradel V, et al. In rheumatoid arthritis patients, HLA-DRB1*04:01 and rheumatoid nodules are associated with ACPA to a particular fibrin epitope. Front Immunol. 2021;12:692041. doi: 10.3389/fimmu.2021.692041, PMID 34248985.
Regueiro C, Casares-Marfil D, Lundberg K, Knevel R, Acosta-Herrera M, Rodriguez-Rodriguez L, et al. HLA-b*08 identified as the most prominently associated major histocompatibility complex locus for anti-carbamylated protein antibody-positive/anti-cyclic citrullinated peptide-negative rheumatoid arthritis. Arthritis Rheumatol. 2021 Jun;73(6):1054-64. doi: 10.1002/art.41538, PMID 33300051.
Cai Y, Liang R, Xiao S, Huang Q, Zhu D, Shi GP, et al.. Circ_0088194 Promotes the Invasion and Migration of Rheumatoid Arthritis Fibroblast-Like Synoviocytes via the miR-766-3p/MMP2 Axis. Front Immunol. 2021;12:628654. doi: 10.3389/fimmu.2021.628654, PMID 33692802.
Zhi L, Liang J, Huang W, Ma J, Qing Z, Wang XC. Circ_AFF2 facilitates the proliferation and inflammatory response of fibroblast-like synoviocytes in rheumatoid arthritis via the miR-375/TAB2 axis. Exp Mol Pathol. 2021 Mar;119:104617. doi: 10.1016/j.yexmp.2021.104617, PMID 33535081.
Luo Z, Chen S, Chen X. CircMAPK9 promotes the progression of fibroblast-like synoviocytes in rheumatoid arthritis via the miR-140-3p/PPM1A axis. J Orthop Surg Res. 2021 Jun 21;16(1):395. doi: 10.1186/s13018-021-02550-y, PMID 34154607.
Zitnay JL, Li Y, Qin Z, San BH, Depalle B, Reese SP, et al. Molecular level detection and localization of mechanical damage in collagen enabled by collagen hybridizing peptides. Nat Commun. 2017 Mar;8:14913. doi: 10.1038/ncomms14913, PMID 28327610.
Zhang J, Lei H, Li X. LncRNA SNHG14 contributes to proinflammatory cytokine production in rheumatoid arthritis via the regulation of the miR-17-5p/MINK1-JNK pathway. Environ Toxicol. 2021 Dec;36(12):2722-30. doi: 10.1002/tox.23302, PMID 34791664.
Xiao J, Wang R, Zhou W, Cai Z, Chen Y, Hu J, et al. LncRNA NEAT1 regulates the proliferation and production of inflammatory cytokines in rheumatoid arthritis fibroblast-like synoviocytes by targeting miR-204-5p. Hum Cell. 2021;34(2):372-82. doi: 10.1007/s13577-020-00467-5, PMID 33389185.
Zhang J, Gao FF, Xie J. LRl. 00152/NF-κB feedback loop promotes fibroblast-like synovial cell inflammation in rheumatoid arthritis via regulating miR-103a/TAK1 axis and YY1 expression. Immun Inflam Dis. 2021;9(3):681-93. doi: 10.1002/iid3.418, PMID 34184927.
Jiang H, Fan C, Lu Y, Cui X, Liu J. Astragaloside regulates lncRNA LOC100912373 and the miR-17-5p/PDK1 axis to inhibit the proliferation of fibroblast-like synoviocytes in rats with rheumatoid arthritis. Int J Mol Med. 2021;48(1):1-10. doi: 10.3892/ijmm.2021.4963, PMID 34013364.
Huang Q, Xu WD, Su LC, Liu XY, Huang AF. Association of CD40 gene polymorphisms with systemic lupus erythematosus and rheumatoid arthritis in a Chinese Han population. Front Immunol. 2021 Apr 22;12:642929. doi: 10.3389/fimmu.2021.642929, PMID 33968033.
Chan HC, Wang SC, Lin CH, Lin YZ, Li RN, Yen JH. A novel CD209 polymorphism is associated with rheumatoid arthritis patients in Taiwan. J Clin Lab Anal. 2021;35(5):e23751. doi: 10.1002/jcla.23751, PMID 33792986.
Cieśla M, Kolarz B, Majdan M, Darmochwał-Kolarz D. Plasma micro-RNA-22 is associated with disease activity in well-established rheumatoid arthritis. Clin Exp Rheumatol. 2022;40(5):945-51. doi: 10.55563/clinexprheumatol/zdhkrp, PMID 34369363.
Hussain MZ, Mahjabeen I, Khan MS, Mumtaz N, Maqsood SU, Ikram F, et al. Genetic and expression deregulation of immunoregulatory genes in rheumatoid arthritis. Mol Biol Rep. 2021 Jun;48(6):5171-80. doi: 10.1007/s11033-021-06518-3, PMID 34196898.
Hosseini N, Tahoori MT, Mohammadzadeh A, Zarei Jaliani H, Bitaraf Sani M, Soleimani Salehabadi H. IRAK1 gene polymorphism in rheumatoid arthritis. Immunol Investig. 2021;50(2-3):304-21. doi: 10.1080/08820139.2020.1764028, PMID 32507051.
Liu X, Peng L, Li D, He C, Xing S, Wang Y, et al. The impacts of IL1R1 and IL1R2 genetic variants on rheumatoid arthritis risk in the Chinese Han population: A case-control study. Int J Gen Med. 2021;14:2147-59. doi: 10.2147/IJGM.S291395, PMID 34093035.
Xie Q, Xu WD, Pan M, Lan YY, Liu XY, Su LC et al. Association of IL-35 expression and gene polymorphisms in rheumatoid arthritis. Int Immunopharmacol. 2021 Feb;90:107231. doi: 10.1016/j.intimp.2020.107231. PMID 33307515.
Hao Y, Xie L, Xia J, Liu Z, Yang B, Zhang M. Plasma interleukin-21 levels and genetic variants are associated with susceptibility to rheumatoid arthritis. BMC Musculoskelet Disord. 2021;22(1):1-9. doi: 10.1186/s12891-021-04571-1, PMID 34344450.
Firestein GS, Zvaifler NJ. How important are T cells in chronic rheumatoid synovitis?: II. T cell-independent mechanisms from beginning to end. Arthritis Rheum. 2002;46(2):298-308. doi: 10.1002/art.502, PMID 11840432.
Pincus T, Callahan LF. Taking mortality in rheumatoid arthritis seriously—predictive markers, socioeconomic status, and comorbidity. J Rheumatol. 1986;13(5):841-5. PMID 3820193.
Yelin E, Wanke LA. An assessment of the annual and long-term direct costs: the impact of poor function and functional decline. Arthritis Rheum. 1999;42(6):1209-18. doi: 10.1002/1529-0131(199906)42:6<1209::AID-ANR18>3.0.CO;2-M, PMID 10366114.
Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide rheumatoid arthritis investigators group. Arch Intern Med. 1999;159(21):2542-50. doi: 10.1001/archinte.159.21.2542, PMID 10573044.
Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2002;137(9):726-33. doi: 10.7326/0003-4819-137-9-200211050-00007, PMID 12416946.
Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38(6):727-35. doi: 10.1002/art.1780380602.
Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med. 2000;343(22):1594-602. doi: 10.1056/NEJM200011303432202, PMID 11096166.
Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human Antitumor Necrosis Factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48(1):35-45. doi: 10.1002/art.10697, PMID 12528101.
Blumenauer B, Judd M, Cranney A, Burls A, Coyle D, Hochberg M, et al. Etanercept for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev. 2003;4(4):CD004525. doi: 10.1002/14651858.CD004525, PMID 14584021.
Humira (adalimumab) [package insert]. Abbott Park, IL: Abbott Laboratories [cited Dec 7, 2004]. Available from: http://fda.gov/cder/foi/label/2002/adalabb123102LB.htm#clin.
Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatol (Oxf Engl). 2003;42(5):617-21. doi: 10.1093/rheumatology/keg263, PMID 12709536.
Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med. 2004;350(21):2167-79. doi: 10.1056/NEJMra032906, PMID 15152062.
Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, et al. Repeated therapy with monoclonal antibody to tumor necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet. 1994;344(8930):1125-7. doi: 10.1016/s0140-6736(94)90632-7, PMID 7934495.
Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of antitumor necrosis factor a monoclonal antibody combined with low dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41(9):1552-63. doi: 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W, PMID 9751087.
Shingu M, Nagai Y, Isayama T, Naono T, Nobunaga M, Nagai Y. The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase production by human chondrocytes and TIMP production by synovial cells and endothelial cells. Clin Exp Immunol. 1993;94(1):145-9. doi: 10.1111/j.1365-2249.1993.tb05992.x, PMID 8403497.
American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum. 2002;46(2):328-46. doi: 10.1002/art.10148, PMID 11840435.
Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 1998;41(12):2196-204. doi: 10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2, PMID 9870876.
Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002;46(3):614-24. doi: 10.1002/art.10141, PMID 11920396.
Fleischmann RM, Schechtman J, Bennett R, Handel ML, Burmester GR, Tesser J, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial. Arthritis Rheum. 2003;48(4):927-34. doi: 10.1002/art.10870, PMID 12687534.
Cohen SB, Moreland LW, Cush JJ, Greenwald MW, Block S, Shergy WJ, et al. A multicentre, double-blind, randomised, placebo-controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis. 2004;63(9):1062-8. doi: 10.1136/ard.2003.016014, PMID 15082469.
Yang BB, Baughman S, Sullivan JT. Pharmacokinetics of anakinra in subjects with different levels of renal function. Clin Pharmacol Ther. 2003;74(1):85-94. doi: 10.1016/S0009-9236(03)00094-8, PMID 12844139.
Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell co-stimulation. Annu Rev Immunol. 1996;14:233-58. doi: 10.1146/annurev.immunol.14.1.233, PMID 8717514.
Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med. 2003;349(20):1907-15. doi: 10.1056/NEJMoa035075, PMID 14614165.
Kremer J, Shergy W, Tindall E, et al. Sustained clinical efficacy demonstrated by the selective co-stimulation modulator abatacept (CTLA4Ig) in combination with methotrexate at 2 years in rheumatoid arthritis patients with an inadequate response to methotrexate. Abstract presented at 68th Annual Scientific Meeting. the American College of Rheumatology. San Antonio: Tex; Oct 16-21, 2004:Abstract S351.
Dougados M, Westhovens R, Williams St Clair E, et al. Sustained remission and major clinical response at 2 years shown with abatacept (CTLA4Ig) in combination with methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate. Abstract presented at 68th Annual Scientific Meeting. the American College of Rheumatology. San Antonio: Tex; Oct 16-21, 2004:Abstract S359.
Moreland L, Weisman M, Alten R, et al. Abatacept (CTLA4Ig) in combination with methotrexate for the treatment of rheumatoid arthritis: favorable safety and tolerability profile sustained over 2 years. Abstract presented at 68th Annual Scientific Meeting. the American College of Rheumatology. San Antonio: Tex; Oct 16-21, 2004:Abstract S1475.
Kremer J, Westhovens R, Moreland L, et al. Efficacy and safety of the selective co-stimulation modulator abatacept with methotrexate for treating rheumatoid arthritis: 1-year clinical and radiographic results from the phase 3 AIM (abatacept in Inadequate responders to methotrexate) Trial. In: Program book supplement: late breaking and fellow. Abstracts of the American college of rheumatology 68th annual scientific meeting. San Antonio: Tex; Oct 16-21, 2004:Abstract L2.
Edwards JCW, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford). 2001;40(2):205-11. doi: 10.1093/rheumatology/40.2.205, PMID 11257159.
Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83(2):435-45, PMID 7506951.
Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350(25):2572-81. doi: 10.1056/NEJMoa032534, PMID 15201414.
Stahl HD, Szczepanski L, Szechinski J, et al. Rituximab in rheumatoid arthritis: efficacy and safety from a randomised controlled trial. Ann Rheum Dis. 2003;62;Suppl:0P004.
Nishimoto N, Kishimoto T, Yoshizaki K. Anti-interleukin 6 receptor antibody treatment in rheumatic disease. Ann Rheum Dis. 2000;59;Suppl 1:i21-7. doi: 10.1136/ard.59.suppl_1.i21, PMID 11053081.
Madhok R, Crilly A, Watson J, Capell HA. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis. 1993;52(3):232-4. doi: 10.1136/ard.52.3.232, PMID 8484679.
Sato K, Tsuchiya M, Saldanha J, Koishihara Y, Ohsugi Y, Kishimoto T, et al. Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res. 1993;53(4):851-6. PMID 8428365.
Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2004;50(6):1761-9. doi: 10.1002/art.20303, PMID 15188351.
Maini RN, Taylor PC, Pavelka K, et al. Efficacy of IL-6 receptor antagonist MRA in rheumatoid arthritis patients with an incomplete response to methotrexate (CHARISMA). RA: randomized clinical trials. Abstract presented at 67th Annual Scientific Meeting. the American College of Rheumatology. Orlando: Fla; Oct 23-28, 2003:Abstract S1704.
Harris ED. Clinical features of rheumatoid arthritis. In: Ruddy S, Harris ED, Sledge CB, Kelley WN, editors. Kelley’s textbook of rheumatology. 7th ed. Philadelphia: W B Saunders; 2005. p. 1043-78.
Akil M, Amos RS. ABC of rheumatology. Rheumatoid arthritis—I: clinical features and diagnosis. BMJ. 1995;310(6979):587-90. doi: 10.1136/bmj.310.6979.587, PMID 7888939.
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315-24. doi: 10.1002/art.1780310302, PMID 3358796.
Saraux A, Berthelot JM, Chalès G, Le Henaff C, Thorel JB, Hoang S, et al. Ability of the American College of Rheumatology 1987 criteria to predict rheumatoid arthritis in patients with early arthritis and classification of these patients two years later. Arthritis Rheum. 2001;44(11):2485-91. doi: 10.1002/1529-0131(200111)44:11<2485::aid-art428>3.0.co;2-s, PMID 11710704.
Scottish Intercollegiate Guidelines Network. Management of early rheumatoid arthritis; Dec 2000. SIGN No. 48 [cited Jul 19, 2005]. Available from: http://www.sign.ac.uk/guidelines/fulltext/48/index.html.
Lin C-Y, Nguyen UTN, Hsieh H-Y, Tahara H, Chang Y-S, Wang B-Y, et al. Peptide-based electrochemical sensor with nanogold enhancement for detecting rheumatoid arthritis. Talanta. 2022 Jan 15;236:122886. doi: 10.1016/j.talanta.2022.122886, PMID 34736325.
Morales-Ivorra I, González-Pérez S, Garrido-Castro JL, et al. Automatic detection of inflamed joints in rheumatoid arthritis using thermography and machine learning. PLOS ONE. 2020;15(9):e0238987. doi: 10.1371/journal.pone.0238987.
Nasra S, Bhatia DD, Kumar A. Recent advances in nanoparticle-based drug delivery system for rheumatoid arthritis Treatment 2022. Nanoscale Adv.
Pathade V, Nene S, Ratnam S, Khatri DK, Raghuvanshi RS, Singh SB, et al. Emerging insights of peptide-based nanotherapeutics for effective management of rheumatoid arthritis. Life Sci. 2023;312:121257. doi: 10.1016/j.lfs.2022.121257, PMID 36462722.
Elkomy MH, Alruwaili NK, Elmowafy M, Shalaby K, Zafar A, Ahmad N, et al. Surface-Modified Bilosomes nanogel bearing a natural plant alkaloid for safe management of rheumatoid arthritis inflammation. Pharmaceutics. 2022 Mar;14(3):563. doi: 10.3390/pharmaceutics14030563, PMID 35335939.
Prasad B, McGeough C, Eakin A, Ahmed T, Small D, Gardiner P, et al. ATRPred: A machine learning-based tool for clinical decision-making of anti-TNF treatment in rheumatoid arthritis patients. PLOS Comp Biol. 2022;18(7):e1009542. doi: 10.1371/journal.pcbi.1009542, PMID 34329353.
Mane RR, Kale PP. The roles of HDAC with IMPDH and mTOR with JAK as future targets in the treatment of rheumatoid arthritis with combination therapy. J Complement Integr Med. 2022 Oct 4;20(1):11-20. doi: 10.1515/jcim-2022-0114, PMID 36409592.
Chen MS, Sitorus MA, Kuo CH, Kuo WW, Chen TS, Fu CY et al. Epigallocatechin-3-gallate pretreatment improves autologous adipose-derived stem cells against rheumatoid arthritis-induced neuroinflammation in the brain of collagen-induced rats. Neurotox Res. 2022;40(5):1223-34. doi: 10.1007/s12640-022-00406-9, PMID 34934771.
Meng X, Zhang X, Su X, Liu X, Ren K, Ning C, et al. Daphnes Cortex and its licorice-processed products suppress inflammation via the TLR4/NF-κB/NLRP3 signaling pathway and regulation of the metabolic profile in the treatment of rheumatoid arthritis. J Ethnopharmacol. 2022;283:114657. doi: 10.1016/j.jep.2021.114657, PMID 34600080.
Pham DT, Thao NTP, Thuy BTP, Van De T, Nguyen TQC, Nguyen NN. Thao Silk fibroin hydrogel containing Sesbania sesban L. extract for rheumatoid arthritis treatment. Drug Deliv. 2022;29(1):882-8. doi: 10.1080/10717544.2022.2008131, PMID 35453909.
Sánchez-Laulhé P, Luque-Romero LG, Barrero-García FJ, Biscarri-Carbonero A, Ángela JMIR mHealth uHealth, Blanquero J, Suero-Pineda A, Heredia-Rizo AM, et al. An Exercise and Educational and Self-management Program Delivered With a Smartphone App (CareHand) in Adults With Rheumatoid Arthritis of the Hands: Randomized Controlled Trial. JMIR mHealth uHealth. 2022 Apr 14;10(4):e35462. doi: 10.2196/35462. PMID: 34884101.
Bruno MC, Cristiano MC, Celia C, d’Avanzo N, Mancuso A, Paolino D, et al. Injectable drug delivery systems for osteoarthritis and rheumatoid arthritis. ACS Nano. 2022;16(12):19665-90. doi: 10.1021/acsnano.2c06393, PMID 36512378.
Nornberg AB, Martins CC, Cervi VF, Sari MHM, Cruz L, Luchese EA et al. Transdermal release of methotrexate by cationic starch/poly (vinyl alcohol)-based films as an approach for rheumatoid arthritis treatment. Int J Pharm. 2022;611:121285. doi: 10.1016/j.ijpharm.2021.121285, PMID 34610339.
Feng Z, Fu L, Wang J, Zhu Y, He X, Zhou L, et al. Efficacy of Tripterygium glycosides (TG) in rheumatoid arthritis as a disease-modifying anti-rheumatic drug (DMARD) in combination with conventional DMARDs: A systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 2022;184:106405. doi: 10.1016/j.phrs.2022.106405, PMID 36028187.
Pelechas E, Drosos AA. State-of-the-art glucocorticoid-targeted drug therapies for the treatment of rheumatoid arthritis. Expert Opin Pharmacother. 2022;23(6):703-11. doi: 10.1080/14656566.2022.2049238, PMID 35313795.
Ben Mrid RB, Bouchmaa N, Ainani H, El Fatimy R, Malka G, Mazini L. Anti-rheumatoid drug advancements: new insights into the molecular treatment of rheumatoid arthritis. Biomed Pharmacother. 2022 Oct;151:113126. doi: 10.1016/j.biopha.2022.113126. PMID 35643074.
Li X, Wang H, Zou X, Su H, Li C. Methotrexate-loaded folic acid of solid-phase synthesis conjugated gold nanoparticles targeted treatment for rheumatoid arthritis. Eur J Pharm Sci. 2022;170:106101. doi: 10.1016/j.ejps.2021.106101, PMID 34936935.
Jaaffer MD, Al-Ogaidi IAZ, Zaidan ZA. Developing gold-resveratrol nanoconjugates for management of rheumatoid arthritis (RA). Egypt J Hosp Med. 2022;89(2):6637-45. doi: 10.21608/ejhm.2022.270744.
Kofoed Andersen C, Khatri S, Hansen J, Slott S, Pavan Parvathaneni R, Mendes AC, et al. Carbon nanotubes-potent carriers for targeted drug delivery in rheumatoid arthritis. Pharmaceutics. 2021 Apr 1;13(4):453. doi: 10.3390/pharmaceutics13040453, PMID 33801590.
Marasini N, Er G, Fu C, Subasic CN, Ibrahim J, Skwarczynski M et al. Development of a hyperbranched polymer-based methotrexate nanomedicine for rheumatoid arthritis. Acta Biomater. 2022;142:298-307. doi: 10.1016/j.actbio.2022.01.054, PMID 35114374.
Yu C, Liu H, Guo C, Chen Q, Su Y, Guo H et al. Dextran sulfate-based MMP-2 enzyme-sensitive SR-A receptor targeting nanomicelles for the treatment of rheumatoid arthritis. Drug Deliv. 2022;29(1):454-65. doi: 10.1080/10717544.2022.2032482, PMID 35119317.
He Y, Xin Y, Rosas EC, Alencar LMR, Santos-Oliveira R, Peng X, et al. Engineered high-loaded mixed-monoclonal antibodies (adalimumab, rituximab and trastuzumab) polymeric nanoparticle for rheumatoid arthritis treatment: A proof of concept. J Biomed Nanotechnol. 2020 Aug 1;16(8):1254-66. doi: 10.1166/jbn.2020.2966, PMID 33397555.
Chen H, Sun Y, Xu X, Ye Q. Targeted delivery of methotrexate by modified yeast β-glucan nanoparticles for rheumatoid arthritis therapy. Carbohydr Polym. 2022 Nov 1;284:119183. doi: 10.1016/j.carbpol.2022.119183. PMID 35287902.
Zhao YP, Han JF, Zhang FY, Liao TT, Na R, Yuan XF, et al. Flexible nano-liposomes-based transdermal hydrogel for targeted delivery of dexamethasone for rheumatoid arthritis therapy. Drug Deliv. 2022;29(1):2269-82. doi: 10.1080/10717544.2022.2096718, PMID 35815790.
Mohammadi G, Korani M, Nemati H, Nikpoor AR, Rashidi K, Varmira K, et al. Crocin-loaded nanoliposomes: preparation, characterization, and evaluation of anti-inflammatory effects in an experimental model of adjuvant-induced arthritis. J Drug Deliv Sci Technol. 2022;74:103618. doi: 10.1016/j.jddst.2022.103618.
Morales-Ivorra I, Narváez J, Gómez-Vaquero C, Moragues C, Nolla JM, Narváez JA et al. Assessment of inflammation in patients with rheumatoid arthritis using thermography and machine learning: a fast and automated technique. RMD Open. 2022;8(2):e001963. doi: 10.1136/rmdopen-2021-001963, PMID 35195387.
Taylor PC. The value of sensitive imaging modalities in rheumatoid arthritis. Arthritis Res Ther. 2003;5(5):1-4. doi: 10.1186/ar903, PMID 14519205.
Chi Z, Huang L, Wu D, Long X, Xu X, Jiang H. First assessment of thermoacoustic tomography for in vivo detection of rheumatoid arthritis in the finger joints detection of rheumatoid arthritis in the finger joints. Med Phys. 2022;49(1):84-92. doi: 10.1002/mp.15340, PMID 34767650.
Huang Y, Liu KJ, Chen GW, Liu JF, Mo FQ, Xie YH. Diagnostic value of semi-quantitative grading of musculoskeletal ultrasound in wrist and hand lesions of subclinical synovitis in rheumatoid arthritis. Am J Nucl Med Mol Imaging. 2022;12(1):25-32. PMID 35295888.
Burska AN, Boissinot M, Ponchel F, Vital EM. New strategies for diagnosis and management of rheumatoid arthritis. Rheumatology. 2014;53(1):3-15. doi: 10.1093/rheumatology/ket301.
Zhang X, Zhang X, Yang Y, Zhi K, Chen Y, Zhao J, et al. Association between passive smoking and the risk of rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol. 2022;41(1):1-18. doi: 10.1007/s10067-021-05805-5, PMID 34218393.
Nasra S, Bhatia DD, Kumar A. Recent advances in nanoparticle-based drug delivery system for rheumatoid arthritis Treatment 2022. Nanoscale Adv.
Emery P, Breedveld FC, Dougados M, Kalden JR, Schiff MH, Smolen JS. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis. 2002;61(4):290-7. doi: 10.1136/ard.61.4.290, PMID 11874828.
Keystone EC, Breedveld FC, van der Heijde D, Landewé R, Florentinus S, Arulmani U, et al. Longterm effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extension. J Rheumatol. 2014;41(1):5-14. doi: 10.3899/jrheum.130543, PMID 24241487.
Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet. 2013;381(9877):1541-50. doi: 10.1016/S0140-6736(13)60250-0.
Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367(6):495-507. doi: 10.1056/NEJMoa1109071, PMID 22873530.
Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2006;144(12):865-76. doi: 10.7326/0003-4819-144-12-200606200-00003, PMID 16785475.
Edwards JC, Szczepański L, Szechiński J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell–targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350(25):2572-81. doi: 10.1056/NEJMoa032534, PMID 15201414.
Fleischmann RM, Schechtman J, Bennett R, Handel ML, Burmester GR, Tesser J, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. Arthritis Rheum. 2003;48(4):927-34. doi: 10.1002/art.10870, PMID 12687534.
McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382(9894):780-9. doi: 10.1016/S0140-6736(13)60594-2, PMID 23769296.
Rader RA. (Re)defining biopharmaceutical. Nat Biotechnol. 2008;26(7):743-51. doi: 10.1038/nbt0708-743, PMID 18612293.
Rantapää-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003;48(10):2741-9. doi: 10.1002/art.11223, PMID 14558078.
Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 2004;50(2):380-6. doi: 10.1002/art.20018, PMID 14872479.
Sokolove J, Bromberg R, Deane KD, Lahey LJ, Derber LA, Chandra PE, et al. Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLOS ONE. 2012;7(5):e35296. doi: 10.1371/journal.pone.0035296, PMID 22662108.
Deane KD, O’Donnell CI, Hueber W, Majka DS, Lazar AA, Derber LA, et al. The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an age-dependent manner. Arthritis Rheum. 2010;62(11):3161-72. doi: 10.1002/art.27638, PMID 20597112.
Van de Stadt LA, Witte BI, Bos WH, van Schaardenburg D. A prediction rule for the development of arthritis in seropositive arthralgia patients. Ann Rheum Dis. 2013;72(12):1920-6. doi: 10.1136/annrheumdis-2012-202127, PMID 23178208.
Rakieh C, Nam JL, Hunt L, Hensor EM, Das S, Bissell LA, et al. Predicting the development of clinical arthritis in anti-CCP positive individuals with non-specific musculoskeletal symptoms: a prospective observational cohort study. Ann Rheum Dis. 2015;74(9):1659-66. doi: 10.1136/annrheumdis-2014-205227, PMID 24728331.
Burgers LE, Raza K, van der Helm-van Mil AH. Prospective study of subjects with arthralgia: development of classification criteria for clinically suspect arthralgia of recent onset. Ann Rheum Dis. 2017;76(3):477-85.
Ramos-Remus C, Castillo-Ortiz JD, Aguilar-Lozano L, et al. Unaffected first-degree relatives of patients with rheumatoid arthritis show autoimmunity and a reduced number of natural killer cells. J Rheumatol. 2015;42(10):1829-35.
de Hair MJH, van de Sande MGH, Ramwadhdoebe TH, et al. Features of the synovium of individuals at risk of developing rheumatoid arthritis: implications for understanding preclinical rheumatoid arthritis. Arthritis Rheum. 2013;65(2):269-75.
Published
How to Cite
Issue
Section
Copyright (c) 2023 Rajni Kaur, Hitesh Kumar Dewangan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
